

Figure 1: X-Ray Powder Diffraction Pattern for Form A of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 2: DSC/TGA Thermogram for Form A of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 3: X-Ray Powder Diffraction Pattern for Form B of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 4: X-Ray Powder Diffraction Pattern for Form C of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 5: DSC/TGA Thermogram for Form C of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 6: X-Ray Powder Diffraction Pattern for Form D of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 7: DSC/TGA Thermogram for Form D of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 8: X-Ray Powder Diffraction Pattern for Form E of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 9: DSC/TGA Thermogram for Form E of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 10: X-Ray Powder Diffraction Pattern for Form F of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 11: X-Ray Powder Diffraction Pattern for Form G of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 12: Human parental MCF7 xenograft anti-tumour efficacy study in mouse with *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 13: Human Y537S ESR1 mutant MCF7 xenograft anti-tumour efficacy study in mouse with *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 14: Human ESR1 mutant breast cancer patient derived xenograft CTC174 anti-tumour efficacy study in mouse with *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine




Figure 15: Human ESR1 mutant breast cancer patient derived xenograft CTC174 anti-tumour efficacy study in mouse with a combination of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine and palbociclib




Figure 16: Human ESR1 mutant breast cancer patient derived xenograft CTC174 anti-tumour efficacy study in mouse with a combination of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6*S*,8*R*)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[4,3-*f*]isoquinolin-6-yl)pyridin-3-amine and vistusertib (AZD2014)

